| Health / Medical Topics |
Gp100:44-59
A synthetic peptide vaccine consisting of the amino acids 44 through 59 of the glycoprotein 100 (gp100) melanoma antigen. Vaccination with gp100_44-59 may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for gp100, resulting in decreased tumor growth. (NCI Thesaurus)
YOU MAY ALSO LIKE
A peptide vaccine consisting of the amino acids 280 through 288 of the melanoma antigen glycoprotein 100 (gp100) with potential antineoplastic…
A vaccine consisting of the amino acids 280 through 288 of the melanoma antigen glycoprotein 100 (gp100) with potential antineoplastic activity. …
A synthetic peptide cancer vaccine consisting of amino acid residues 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen, with a…
A synthetic peptide vaccine consisting of the amino acids 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen. Vaccination with…
A synthetic peptide vaccine consisting of amino acids 17 through 25 of the glycoprotein 100 (gp100) melanoma antigen. Vaccination with gp100_17-25…
A peptide consisting of amino acid residues 154 through 162 of the melanoma-melanocyte antigen gp100. Vaccination with gp100:154-162 peptide may enhance tumor-specific…
